CASE COMMENT : ABUSE OF DOMINANT POSITION - PREDATORY PRICES - GENERIC DRUGS

Predatory pricing: The French Competition Council imposes a heavy fine for predatory prices aimed at impending the growth of generic medicines in hospitals (GlaxoSmithKline)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. Cons. conc. dec. no. 07-D-09 of 14 March 2007 relating to practices implemented by the GlaxoSmithKline France laboratory Two decisions, one French, the other Community, relating to predatory pricing, differ significantly on the criteria applied to classify predation practices (see ConcurrencesNo. 2-2007, Chronique Pratiques unilatérales, Note L. F., Le TPI confirme la condamnation de Wanadoo pour des pratiques de prix prédateurs, TPICE, 30 January 2007, France Télécom SA (Anciennement Wanadoo Interactive SA) c/ Commission, aff. T-340/03, Case T-340/03.). In a major decision of March 14, 2007, the French Competition Council severely sanctions the French

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Anne Wachsmann, Laurent Flochel, Charles Pommies, Predatory pricing: The French Competition Council imposes a heavy fine for predatory prices aimed at impending the growth of generic medicines in hospitals (GlaxoSmithKline), 14 March 2007, Concurrences N° 2-2007, Art. N° 13488, pp. 110-115

Visites 6835

All reviews